<DOC>
	<DOCNO>NCT02397434</DOCNO>
	<brief_summary>A radical cystectomy + extend pelvic lymph node dissection consider treatment choice patient muscle invasive bladder cancer ( MIBC ) . Despite aggressive treatment outcome poor ultimately , 30 % patient ≥pT3 tumor develop pelvic recurrence . One- 2-years survival patient develop local recurrence cystectomy 8 % 3 % respectively , median survival &lt; 4 month . For patient lymph node recurrence prognosis somewhat well , nevertheless still disappoint report 1- 2 year survival 42 % 11 % respectively . The investigator hypothesize early implementation external beam radiotherapy ( EBRT ) i.e . adjuvant setting , prevent local lymph node recurrence improve disease free- overall survival local recurrence link development distant metastasis . Adjuvant EBRT test prospective randomize trial result 20 % increase 5-year disease free survival . Despite impressive result , severe intestinal toxicity rate hamper enthusiasm use adjuvant EBRT , till . In last decade , great technological advancement EBRT planning , intensity modulate arc therapy ( IMAT ) , position realise . This result good coverage target volume spar normal tissue ( mainly small bowel ) precise delivery EBRT . Therefore , desirable reconsider use adjuvant EBRT select MIBC patient .</brief_summary>
	<brief_title>Adjuvant Radiotherapy After Cystectomy Muscle Invasive Bladder Cancer</brief_title>
	<detailed_description>The investigator plan perform prospective phase 2 study include 76 patient . Radiation median dose 50 Gy 25 fraction deliver IMAT pelvic lymph node region . If positive surgical margin , operative bladder bed include radiation field . A simultaneous integrate boost 64 Gy positive lymph node deliver . Pathological evaluation cystectomy specimen include : tumor stage grade , area necrosis ( absolute relative ) , micro vessel density , epidermal growth factor receptor .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>muscle invasive bladder cancer : ≥ pathological tumor stage ( p ) T3 stage + presence lymphovascular invasion pathological examination pT4 &lt; 10 lymph node remove positive lymph node positive surgical margin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>assessment QOL ( EORTC QLQ-C30 )</keyword>
</DOC>